Dataset Information

B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV.

ABSTRACT: Monoclonal antibodies (mAbs) are a focus in vaccine and therapeutic design to counteract severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants. Here, we combined B cell sorting with single-cell VDJ and RNA sequencing (RNA-seq) and mAb structures to characterize B cell responses against SARS-CoV-2. We show that the SARS-CoV-2-specific B cell repertoire consists of transcriptionally distinct B cell populations with cells producing potently neutralizing antibodies (nAbs) localized in two clusters that resemble memory and activated B cells. Cryo-electron microscopy structures of selected nAbs from these two clusters complexed with SARS-CoV-2 spike trimers show recognition of various receptor-binding domain (RBD) epitopes. One of these mAbs, BG10-19, locks the spike trimer in a closed conformation to potently neutralize SARS-CoV-2, the recently arising mutants B.1.1.7 and B.1.351, and SARS-CoV and cross-reacts with heterologous RBDs. Together, our results characterize transcriptional differences among SARS-CoV-2-specific B cells and uncover cross-neutralizing Ab targets that will inform immunogen and therapeutic design against coronaviruses.

SUBMITTER: Scheid JF

PROVIDER: S-EPMC8064835 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV.

Scheid Johannes F JF Barnes Christopher O CO Eraslan Basak B Hudak Andrew A Keeffe Jennifer R JR Cosimi Lisa A LA Brown Eric M EM Muecksch Frauke F Weisblum Yiska Y Zhang Shuting S Delorey Toni T Woolley Ann E AE Ghantous Fadi F Park Sung-Moo SM Phillips Devan D Tusi Betsabeh B Huey-Tubman Kathryn E KE Cohen Alexander A AA Gnanapragasam Priyanthi N P PNP Rzasa Kara K Hatziioanno Theodora T Durney Michael A MA Gu Xiebin X Tada Takuya T Landau Nathaniel R NR West Anthony P AP Rozenblatt-Rosen Orit O Seaman Michael S MS Baden Lindsey R LR Graham Daniel B DB Deguine Jacques J Bieniasz Paul D PD Regev Aviv A Hung Deborah D Bjorkman Pamela J PJ Xavier Ramnik J RJ

Cell 20210424 12

Monoclonal antibodies (mAbs) are a focus in vaccine and therapeutic design to counteract severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants. Here, we combined B cell sorting with single-cell VDJ and RNA sequencing (RNA-seq) and mAb structures to characterize B cell responses against SARS-CoV-2. We show that the SARS-CoV-2-specific B cell repertoire consists of transcriptionally distinct B cell populations with cells producing potently neutralizing antibodies (nAbs) loc ...[more]

PMID: 34015271

Similar Datasets

Project description:Several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants have arisen that exhibit increased viral transmissibility and partial evasion of immunity induced by natural infection and vaccination. To address the specific antibody targets that were affected by recent viral variants, we generated 43 monoclonal antibodies (mAbs) from 10 convalescent donors that bound three distinct domains of the SARS-CoV-2 spike. Viral variants harboring mutations at K417, E484, and N501 could escape most of the highly potent antibodies against the receptor binding domain (RBD). Despite this, we identified 12 neutralizing mAbs against three distinct regions of the spike protein that neutralize SARS-CoV-2 and variants of concern (VOCs), including B.1.1.7 (alpha), P.1 (gamma), and B.1.617.2 (delta). Notably, antibodies targeting distinct epitopes could neutralize discrete variants, suggesting that different variants may have evolved to disrupt the binding of particular neutralizing antibody classes. These results underscore that humans exposed to the first pandemic wave of prototype SARS-CoV-2 possess neutralizing antibodies against current variants and that it is critical to induce antibodies targeting multiple distinct epitopes of the spike that can neutralize emerging variants of concern. IMPORTANCE We describe the binding and neutralization properties of a new set of human monoclonal antibodies derived from memory B cells of 10 coronavirus disease 2019 (COVID-19) convalescent donors in the first pandemic wave of prototype SARS-CoV-2. There were 12 antibodies targeting distinct epitopes on spike, including two sites on the RBD and one on the N-terminal domain (NTD), that displayed cross-neutralization of VOCs, for which distinct antibody targets could neutralize discrete variants. This work underlines that natural infection by SARS-CoV-2 induces effective cross-neutralization against only some VOCs and supports the need for COVID-19 vaccination for robust induction of neutralizing antibodies targeting multiple epitopes of the spike protein to combat the current SARS-CoV-2 VOCs and any others that might emerge in the future.

Dataset Information

B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV.

Publications

B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets